DANBURY, Conn., May 17 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. today announced that Jennifer Good, President and Chief Executive Officer of Penwest, will be presenting at the Bank of America 2007 Healthcare Conference which will be held at the Four Seasons Hotel in Las Vegas, Nevada. Ms. Good’s presentation is scheduled to begin at 8:40 a.m. Pacific Daylight Time on May 30, 2007.
Ms. Good will also be presenting at the FTN Midwest Healthcare Conference at the Four Seasons Hotel in New York City on June 6, 2007. Ms. Good’s presentation is scheduled to begin at 11:20 a.m. Eastern Daylight Time.
Penwest Pharmaceuticals
Penwest is a specialty pharmaceutical company dedicated to bringing to the marketplace innovative products that help improve the lives of patients. The Company’s goal is to identify, develop and commercialize prescription products that address unmet medical needs, primarily for diseases of the nervous system. At the core of this strategy, Penwest applies drug delivery technologies, including its own proprietary technologies, to new and existing compounds to enhance their therapeutic profiles. The launch by Endo Pharmaceuticals in mid-2006 of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) formulated with the Company’s TIMERx(R) extended release delivery technology demonstrates the execution of this strategy and the value of the Company’s TIMERx(R) technology. The Company is currently applying its expertise to a pipeline of potential products that are in various stages of development. The Company intends to commercialize these products independently or through third party alliances.
Forward-Looking Statement
The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause Penwest’s actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” and similar expressions are intended to identify forward-looking statements. Important factors that could cause results to differ materially include: risks relating to the commercial success of Opana ER and our reliance on Endo for the commercial success of Opana ER; regulatory risks relating to drugs in development, including the timing and outcome of regulatory action; uncertainty of success of collaborations; the timing of clinical trials and whether the results of clinical trials will warrant further clinical trials or warrant submission of an application for regulatory approval of, or the regulatory approval of, the product that is the subject of the trial; actual and potential competition; the need for capital; and other risks as set forth under the caption Risk Factors in Penwest’s Quarterly Report on Form 10Q filed with the Securities and Exchange Commission on May 10, 2007, which risk factors are incorporated herein by reference.
The forward-looking statements contained in this press release speak only as of the date of the statement made. Penwest disclaims any intention or obligation to update any forward-looking statements.
TIMERx is a registered trademark of Penwest. All other trademarks referenced herein are the property of their respective owners.
Contacts: Investors: Media: Diane D’Alessandro Laura Walters (203) 796-3706 Kekst and Company (877) 736-9378 (212) 521-4800
Penwest
CONTACT: Investors, Diane D’Alessandro, +1-203-796-3706, +1-877-736-9378;or Media, Laura Walters of Kekst and Company, +1-212-521-4800, for Penwest
